Introduction {#s1}
============

The coronavirus disease (COVID-19) pandemic in 2019/2020 became a significant problem not only for first-line healthcare but also for cancer patients, who are at the risk of severe or fatal outcome of potential infection. In recently published papers about radiotherapy (RT) in various cancers, there are suggestions to use more hypofractionated RT (HFRT) regimens during the COVID-19 pandemic to reduce overall treatment time ([@B1]). Unfortunately, HFRT in soft tissue sarcomas (STS) is rarely mentioned and underestimated. SARS-CoV-2 infection in a tertiary STS clinic or RT department might cause a shortage of experienced staff by putting them in quarantine. What is more, the interrupted treatment cannot be continued in other institutions with the maintenance of high-quality care due to lack of necessary knowledge, experience, and equipment. Perioperative conventionally fractionated RT (CFRT), namely between 1.8 and 2.0 Gy per fraction by 5 to 7 weeks, is considered to be a standard regimen in STS ([@B2]). There is growing evidence that preoperative HFRT could be also a possible therapeutic approach and its wide introduction may be a controversial but necessary solution.

Rationale for Preoperative Approach {#s2}
===================================

Preoperative RT in STS is not widely accepted due to the higher risk of postoperative wound complications. However, wound complications, even serious, are usually manageable and reversible, while late toxicity, manifested as complications related to fibrosis, is commonly permanent and can lead to severe impairment of patient\'s function and quality of life. In a phase III randomized clinical trial that compared preoperative and postoperative RT in STS, wound complications occurred in 35% of patients in the preoperative group and in 17% in the postoperative group ([@B3]). After prolonged follow-up, late toxicity was observed more frequently in the postoperative arm than in the preoperative arm without any significant differences in local control and survival ([@B4]). The preoperative RT has more advantages i.e., visible tumor volume, less healthy tissues within irradiated volume, lower total dose, better tissue oxygenation, and lower risk of tumor cell seeding during surgery. Moreover, preoperative RT may provide substantial benefit for patients with locally advanced disease, allowing conservative or limb-sparing surgery in marginally-resectable or unresectable STS ([@B5]). Finally, cost-effectiveness analysis supports preoperative RT in STS ([@B6]).

Rationale for Hypofractionation {#s3}
===============================

HFRT has a clinical rationale. HFRT regimens could significantly shorten overall treatment time. Decreased exposure to potential SARS-CoV-2 infection in a hospital as well as compliance with treatment, convenience and cost favor HFRT. Additionally, HFRT has a radiobiological rationale. Basing on the linear-quadratic model, a larger dose per fraction applied to tumors with a lower α/β ratio should result in better tumor control. Heterogeneity of STS translates into a wide spectrum of radiosensitivity, however, for most STS subtypes α/β ratio is considered as lower than 10 Gy ([@B7]). For example, calculated liposarcoma and rhabdomyosarcoma α/β ratios were as low as 0.4 and 2.8 Gy, respectively ([@B8]). Furthermore, assuming low α/β ratio for STS and better responsiveness to a larger fraction size, HFRT may allow de-escalation of total dose with constant tumor control. That may result in decreased toxicity from surrounding tissues. For purposes of comparison of the different fractionation schedules in this review, the equivalent dose in 2-Gy fractions (EQD2) was calculated assuming the α/β ratio for STS of 4 Gy, as in calculations performed in other studies ([@B2], [@B7]). The results were presented in [Table 1](#T1){ref-type="table"}.

###### 

Preoperative radiotherapy regimens in soft tissue sarcomas in major published studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                            **References**                        **Evidence**                       **N of patients**                       **Dominant preoperative regimen**                                                  **EQD2 α/β 4 Gy**   **Tumors \>10 cm**   **Surgery after RT**   **R0**   **\@years local control**   **All wound complications \@severe[^∧^](#TN2){ref-type="table-fn"}**   **Reported late toxicity**   **\@years estimated survival**
  ----------------------------------------- ------------------------------------- ---------------------------------- --------------------------------------- ---------------------------------------------------------------------------------- ------------------- -------------------- ---------------------- -------- --------------------------- ---------------------------------------------------------------------- ---------------------------- --------------------------------
  Conventionally fractionated RT regimens   Pollack et al. ([@B9])                Retrospective cohort               128 (preop) 51 CHT+RT 77 RT             CHT[^\*^](#TN1){ref-type="table-fn"}[^&^](#TN2){ref-type="table-fn"}50 Gy/25 fr.   50 Gy               ND\                  Delayed                92%      \@5y\                       25%\@ND                                                                6%                           ND
                                                                                                                                                                                                                                                                    median\                                              82%                                                                                                                             
                                                                                                                                                                                                                                                                    10 cm                                                                                                                                                                                

                                            O\'Sullivan et al. ([@B3], [@B10])\   Phase III RCT (preop vs. postop)   94 (preop)                              50 Gy/25 fr.                                                                       50 Gy               35%                  Delayed\               84%      \@5y\                       35%\@17%                                                               G2+:\                        \@5y\
                                            Davis et al. ([@B4])                                                                                                                                                                                                                         (3--6 weeks)                    93%                                                                                                fibrosis 32%\                DRFS 67% OS 73%
                                                                                                                                                                                                                                                                                                                                                                                                                            JS 18%\                      
                                                                                                                                                                                                                                                                                                                                                                                                                            edema 15%                    

                                            Zagars et al. ([@B11])                Retrospective cohort               271 (preop)\                            CHT[^\*^](#TN1){ref-type="table-fn"}[^&^](#TN2){ref-type="table-fn"}\              50 Gy               42%                  Delayed\               86%      \@5y\                       ND                                                                     5%                           \@5y\
                                                                                                                     179 CHT+RT\                             50 Gy/25 fr.                                                                                                                (4--6 weeks)                    85%\                                                                                                                            DRFS 64%\
                                                                                                                     92 RT                                                                                                                                                                                               \@10y\                                                                                                                          \@10y\
                                                                                                                                                                                                                                                                                                                         83%                                                                                                                             DRFS 61% DSS 64%

                                            Hui et al. ([@B12])                   Retrospective cohort               67                                      50.4 Gy/28 fr.                                                                     48.7 Gy             ND\                  Delayed\               99%      \@5y\                       41%\@18%                                                               7%                           \@5y\
                                                                                                                                                                                                                                                                    median\              (3--6 weeks)                    93%                                                                                                                             DRFS 68% OS 73%
                                                                                                                                                                                                                                                                    6 cm                                                                                                                                                                                 

                                            Kraybill et al. ([@B13])              Phase II single arm CT             64                                      MAID\                                                                              44 Gy               ND\                  Delayed                91%      \@3y\                       11%\@3%                                                                ND                           \@3y\
                                                                                                                                                             22 Gy/11 fr.\                                                                                          median\                                              90%                                                                                                                             DRFS 65% OS 75%
                                                                                                                                                             MAID\                                                                                                  15 cm                                                                                                                                                                                
                                                                                                                                                             22 Gy/11 fr.\                                                                                                                                                                                                                                                                               
                                                                                                                                                             MAID                                                                                                                                                                                                                                                                                        

                                            Canter et al. ([@B14])                Retrospective cohort               25                                      50 Gy/25 fr.                                                                       50 Gy               36%                  Delayed\               84%      \@3y\                       28%\@16%                                                               ND                           ND
                                                                                                                                                                                                                                                                                         (4--6 weeks)                    100%                                                                                                                            

                                            Yoon et al. ([@B15])                  Phase II single arm CT             20                                      Bevacizumab\                                                                       48.7 Gy             ND\                  Delayed\               ND       \@2y\                       20%\@ND                                                                ND                           \@2y\
                                                                                                                                                             50.4 Gy/28 fr.                                                                                         median\              (6--7 weeks)                    95%                                                                                                                             DRFS 65%
                                                                                                                                                                                                                                                                    8 cm                                                                                                                                                                                 

                                            Shah et al. ([@B16])                  Retrospective cohort               30                                      50 Gy/25 fr.                                                                       50 Gy               40%                  Delayed\               ND       \@5y\                       23%\@20%                                                               ND                           \@5y\
                                                                                                                                                                                                                                                                                         (4--6 weeks)                    100%                                                                                                                            DRFS 61% OS 69%

                                            O\'Sullivan et al. ([@B17])           Phase II single arm CT             59                                      50 Gy/25 fr.                                                                       50 Gy               ND\                  Delayed                93%      \@5y\                       31%\@10%                                                               Moderate:\                   \@5y\
                                                                                                                                                                                                                                                                    median 10 cm                                         88%                                                                                                skin 2%\                     DRFS 67% OS 75%
                                                                                                                                                                                                                                                                                                                                                                                                                            fibrosis 9%\                 
                                                                                                                                                                                                                                                                                                                                                                                                                            JS 7%\                       
                                                                                                                                                                                                                                                                                                                                                                                                                            edema 11%                    

                                            Lewin et al. ([@B18])                 Phase Ib/II single arm CT          9                                       Sunitinib\                                                                         48.7 Gy             ND\                  Delayed\               ND       ND                          ND                                                                     Any G: 78%                   \@2y\
                                                                                                                                                             50.4 Gy/28 fr.                                                                                         median 10 cm         (3--6 weeks)                                                                                                                                                    PFS 44%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                         OS 56%

                                            Canter et al. ([@B19])                Phase I single arm CT              8                                       Sorafenib\                                                                         50 Gy               63%                  Delayed\               75%      \@3y\                       38%\@ND                                                                ND                           \@3y\
                                                                                                                                                             50 Gy/25 fr.                                                                                                                (4--6 weeks)                    100%                                                                                                                            DRFS 42% OS 75%

                                            Wang et al. ([@B20])                  Phase II single arm CT             79                                      50 Gy/25 fr.\                                                                      50 Gy               ND\                  Delayed                76%      \@2y\                       37%\@25%                                                               G2+:\                        \@2y\
                                                                                                                                                             with reduced margins                                                                                   median\                                              94%                                                                                                fibrosis 5%\                 DRFS 65% OS 81%
                                                                                                                                                                                                                                                                    11 cm                                                                                                                                                   JS 4%\                       
                                                                                                                                                                                                                                                                                                                                                                                                                            edema 5%                     

                                            Haas et al. ([@B21])                  Phase I single arm CT              11                                      Pazopanib\                                                                         50 Gy               27%                  Delayed\               ND       \@2y\                       20%\@0%                                                                ND                           \@2y\
                                                                                                                                                             50 Gy/25 fr.                                                                                                                (5--7 weeks)                    91%                                                                                                                             DRFS 82%

                                            Jakob et al. ([@B22])                 Phase Ib/II single arm CT          5                                       Sunitinib\                                                                         48.7 Gy             40%                  Delayed\               100%     \@2y\                       56%\@22%                                                               ND                           \@2y\
                                                                                                                                                             50.4 Gy/28 fr.                                                                                                              (5--8 weeks)                    80%                                                                                                                             DRFS 60%

  Hypofractionated RT regimens              Temple et al. ([@B23])                Prospective register               42                                      Doxorubicin\                                                                       35 Gy               ND                   Delayed\               ND       \@5y\                       15%\@ND                                                                ND                           \@5y\
                                                                                                                                                             30 Gy/10 fr.                                                                                                                (4--6 weeks)                    97%                                                                                                                             OS 79%

                                            Ryan et al. ([@B24])                  Retrospective cohort               25                                      EI\                                                                                35 Gy               ND\                  Delayed\               88%      \@2y\                       ND\@20%                                                                ND                           \@2y\
                                                                                                                                                             28 Gy/8 fr.                                                                                            median\              (4--5 weeks)                    88%                                                                                                                             DRFS 78% OS 84%
                                                                                                                                                                                                                                                                    10 cm                                                                                                                                                                                

                                            MacDermed et al. ([@B25])             Retrospective cohort               34\                                     Ifosfamide\                                                                        35 Gy               32% (\>12 cm)        delayed\               100%     \@5y\                       ND\@17%                                                                Fibrosis 14%\                \@5y (no DM)\
                                                                                                                     included 6 patients with DM             28 Gy/8 fr.                                                                                                                 (4--8 weeks)                    89%                                                                                                edema 17%                    DRFS 53% OS 45%

                                            Meyer et al. ([@B26])                 Phase I single arm CT              16\                                     Sorafenib\                                                                         35 Gy               ND                   Delayed                94%      \@2y\                       38%\@ND                                                                ND                           \@2y\
                                                                                                                     included 2 patients with DM             EI\                                                                                                                                                         100%                                                                                                                            PFS 86%
                                                                                                                                                             28 Gy/8 fr.                                                                                                                                                                                                                                                                                 

                                            Koseła-Paterczyk et al. ([@B27])      Prospective register               272\                                    CHT[^\*^](#TN1){ref-type="table-fn"}[^&^](#TN2){ref-type="table-fn"}\              37.5 Gy             42%                  Immediate\             79%      \@3y\                       all 32% \@12%\                                                         15% all\                     \@5y\
                                                                                                                     61 CHT+RT\                              25 Gy/5 fr.                                                                                                                 (3--7 days)                     81%                         53% CHT+RT 53% \@21%\                                                  23% CHT+RT\                  OS 60%
                                                                                                                     211 RT                                                                                                                                                                                                                          RT 27% \@9%                                                            12% RT                       

                                            Pennington et al. ([@B28])            Retrospective cohort               116                                     CHT[^\*^](#TN1){ref-type="table-fn"}\                                              35 Gy               47%                  Delayed\               93%      \@3y\                       10%\@1%                                                                4%                           \@3y\
                                                                                                                                                             28 Gy/8 fr.                                                                                                                 (2--3 weeks)                    89%\                                                                                                                            DRFS 75% OS 82%\
                                                                                                                                                                                                                                                                                                                         \@6y\                                                                                                                           \@6y\
                                                                                                                                                                                                                                                                                                                         83%                                                                                                                             DRFS 65% OS 67%

                                            Spalek et al. ([@B29])                Phase II single arm CT             29\                                     25 Gy /5 fr.                                                                       37.5 Gy             66%                  Delayed\               93%      \@1y\                       31%\@ND                                                                ND                           \@1y\
                                                                                                                     MLPS only                                                                                                                                                           (6--8 weeks)                    100%                                                                                                                            DRFS 86%

                                            Spalek et al. ([@B5])                 Phase II single arm CT             30\                                     1x AI\                                                                             37.5 Gy             74%                  Delayed\               73%      \@1y\                       23%\@7%                                                                ND                           \@1y\
                                                                                                                     marginally resectable or unresectable   25 Gy/5 fr.\                                                                                                                (6--8 weeks)                    97%                                                                                                                             DRFS 74%
                                                                                                                                                             2x AI                                                                                                                                                                                                                                                                                       

                                            Parsai et al. ([@B30])                Retrospective cohort               16\                                     CHT[^\*^](#TN1){ref-type="table-fn"}\                                              50 Gy               25%                  Immediate\             63%      \@1y\                       31%\@19%                                                               ND                           ND
                                                                                                                     3 CHT+RT\                               30 Gy /5 fr.                                                                                                                (0--7 days)                     100%                                                                                                                            
                                                                                                                     13 RT                                                                                                                                                                                                                                                                                                                               

                                            Kalbasi et al. ([@B31])               Phase II single arm CT             50                                      30 Gy/5 fr.                                                                        50 Gy               24%                  Delayed\               82%      \@2y 94%                    32%\@24%                                                               G1:\                         \@2y\
                                                                                                                                                                                                                                                                                         (2--6 weeks)                                                                                                                       fibrosis 24%\                DRFS 79%
                                                                                                                                                                                                                                                                                                                                                                                                                            JS 11%\                      
                                                                                                                                                                                                                                                                                                                                                                                                                            edema 4%\                    
                                                                                                                                                                                                                                                                                                                                                                                                                            G2:\                         
                                                                                                                                                                                                                                                                                                                                                                                                                            fibrosis 11%\                
                                                                                                                                                                                                                                                                                                                                                                                                                            JS 11%\                      
                                                                                                                                                                                                                                                                                                                                                                                                                            edema 4%                     
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*AI, doxorubicin, ifosfamide; EI, epirubicin, ifosfamide; CHT, chemotherapy; CT, clinical trial; DM, distant metastases; DRFS, distant recurrence-free survival; DSS, disease-specific survival; EQD2, equivalent dose in 2-Gy fractions; G, grade; JS, joint stiffness; MAID, mesna, doxorubicin, ifosfamide, dacarbazine; MLPS, myxoid liposarcomas; ND, no data; OS, overall survival; PFS, progression-free survival; RCT, randomized clinical trial; RT, radiotherapy; STS, soft tissue sarcomas*.

*various regimens were used*.

*only part of a group received chemotherapy*.

*assessed by authors as grade 3 or higher, or requiring reoperation*.

Available Evidence and HFRT Regimens {#s4}
====================================

Preoperative HFRT in STS has been validated in retrospective analyses, prospective registries, and phase I-II clinical trials ([@B5], [@B23]--[@B31]). However, randomized phase III trials comparing preoperative CFRT with HFRT are lacking. As with CFRT, HFRT could be combined with systemic treatment ([@B2]). Despite scarce evidence on the efficacy of perioperative chemotherapy in STS, it is commonly applied as a part of treatment. A combination of RT with targeted therapy is still under investigation giving promising results but also unexpected toxicities ([@B18], [@B21]). The investigated regimens of preoperative RT in STS were summarized in [Table 1](#T1){ref-type="table"} ([@B3]--[@B5], [@B9]--[@B31]). Presented data should be interpreted with caution because analyzed populations were not comparable as they differed with many factors including patients\' characteristics, STS subtypes, tumor size, indications for RT, RT techniques, elective margins, and quality of surgery. Nevertheless, the results of HFRT regimens seem very similar to those of CFRT regimens. The 5-year local control was 82--100% (median 91%) in CFRT and 89 and 97% in two studies on HFRT. Furthermore, the rate of severe wound complications was 0--25% (median 17%) in CFRT and 1--24% (median 18%) in HFRT. It is noticeable, that EQD2 is lower than 50 Gy in the majority of analyzed HFRT regimens.

Discussion {#s5}
==========

Available data suggest that preoperative HFRT in STS is a promising treatment option providing satisfactory local control with acceptable toxicity. Nevertheless, it has been not widely adapted in clinical practice. COVID-19 pandemic may be the appropriate time to rethink RT in STS.

Routine use of preoperative HFRT may be limited by some concerns. One may fear that decreased EQD2 in preoperative HFRT will result in worse local control. However, the current standard of 50 Gy in 2-Gy fractions is not based upon strong evidence coming from randomized clinical trials with various dose levels or fractionation regimens. In the analysis performed by Haas et al. it has been shown that dose-response relationship for local control in preoperative RT is clear only below 28 Gy in 8 fractions of 3.5 Gy (EQD2 = 35 Gy if α/β = 4 Gy) ([@B2]). Above that level, the benefit in local control from increased total dose may be negligible, especially when RT is combined with preoperative chemotherapy or targeted therapy. Data presented in the [Table 1](#T1){ref-type="table"} suggest that this assumption may be correct because local control in all described regimens is higher than 80% despite various EQD2. Interestingly, HFRT regimen described by Koseła-Paterczyk et al. (25 Gy in 5 fractions) given in the majority of patients without preoperative chemotherapy provided lower (but acceptable) local control than regimens with higher fraction and total doses (30 Gy in 5 fractions) or one with the same fractionation regimen but combined with sequential anthracycline-based chemotherapy ([@B5], [@B27], [@B30], [@B31]). The same 5 × 5 Gy regimen without chemotherapy but with delayed surgery resulted in 100% 1-year control rate in patients with myxoid liposarcomas that are considered radiosensitive ([@B29]).

Furthermore, the preoperative approach and hypofractionation in STS remain controversial due to the risk of treatment-related morbidity. Wound complications are serious adverse effects of any preoperative RT in STS. However, this toxicity could be predicted by assessment of patient-related risk factors, such as smoking, diabetes, obesity, and tumor location (lower limbs) ([@B32]). Although larger doses per fraction could theoretically increase the risk of late toxicities, such assumption was neither confirmed in clinical trials with preoperative and definitive HFRT in other neoplasms, i.e., rectal, prostate or lung cancer, nor in presented data regarding HFRT in STS. Moreover, the occurrence of selected late toxicities after combined treatment of STS could be predicted and often reduced. For example, periosteal location of tumor, higher mean and maximal dose to bone as well as volume of bone irradiated to over 40 Gy in 2-Gy fractions increase the risk of pathologic fractures ([@B33]). Proper treatment planning and choice of RT techniques with intensity modulation can significantly reduce both early and late toxicity ([@B17], [@B20]). Thus, taking into account local control and toxicity, the choice of RT regimen should be based on several factors, i.e., patients\' characteristics, tumor location and size, STS subtype and its radiosensitivity, risk of local and distant relapse, availability of equipment, RT techniques, and systemic treatments.

No direct comparison of preoperative CFRT and HFRT regimens in STS was performed in the literature. While randomized clinical trials are still the gold standard, other approaches when investigating various treatments for rare diseases should be considered, such as Bayesian trial design. Moreover, after discussion within the multidisciplinary tumor board, the individualized treatment regimens may be proposed to patients then collected in prospective registries.

Radiation oncologists are not front-line fighters in COVID-19 times, but they can deal with the spread of infection another way. In a global emerging situation of COVID-19 pandemic, the benefits of preoperative HFRT for STS patients may outweigh risks. Besides good efficacy and acceptable toxicity, HFRT decreases the hospital-associated COVID-19 infection risk, as well as the risk of treatment interruption, delay, or its poor quality if performed outside STS tertiary center. Available treatment options and concerns should be discussed with the patient in a shared decision-making process.
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